SCOPUS 정보 검색 플랫폼

British Journal of Cancer

Volumn 85, Issue 2, 2001, Pages 152-156

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer

(6) James, N D a Atherton, P J a Jones, J a Howie, A J a Tchekmedyian, S b Curnow, R T c

a UNIVERSITY OF BIRMINGHAM (United Kingdom)

b Pacific Shores Medical Group (United States)

c MEDAREX INC (United States)

Author keywords

Bispecific antibody; GM CSF; HER2; Immunotherapy; Prostate cancer

Indexed keywords

BISPECIFIC ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MDX H210; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DRUG WITHDRAWAL; DYSPNEA; FOLLOW UP; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; ONCOGENE NEU; PAIN; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOCARCINOMA; AGED; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0034940408 PISSN: 00070920 EISSN: None Source Type: Journal
DOI: 10.1054/bjoc.2001.1878 Document Type: Article

Times cited : (83)

References (29)

1
- 0000905158
- Efficacy and safety of Herceptin (humanized anti-her2 antibody) as a single agent in 222 women with her2 overexpression who relapsed following chemotherapy for metastatic breast cancer
- (1998) Proc of ASCO , vol.17
- Cobleigh, M.A.¹ Vogel, C.L.² Tripathy, D.³ Robert, N.J.⁴ Scholl, S.⁵ Fehrenbacher, L.⁶ Paton, V.⁷ Shak, S.⁸ Lieherman, G.⁹ Slamon, D.¹⁰

2
- 0024995148
- Evaluation of the antibody-dependent cytotoxicity capabilities of individual human monocytes - Role of Fc gamma R1 and Fc gamma R2 and the effects of cytokines at the single cell level
- (1990) J Immunol , vol.145 , pp. 1483-1489
- Connor, R.I.¹ Shen, L.² Fanger, M.W.³

3
- 0033022342
- A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
- (1999) Nature Medicine , vol.5 , pp. 280-285
- Craft, N.¹ Shostak, Y.² Carey, M.³ Sawyers, C.L.⁴

4
- 0031726901
- Apples and oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials [see comments]
- (1998) J Clin Oncol , vol.16 , pp. 3398-3405
- Dawson, N.A.¹

5
- 0027081036
- Bispecific antibodies
- (1992) Critical Rev Immun , vol.12 , pp. 101-121
- Fanger, M.W.¹ Morganelli, P.M.² Guyre, P.M.³

6
- 0028168271
- Prognostic value of c-erbB-2 and epidermal growth factor receptor in stag AI (TI) prostatic adenocarcinoma
- (1994) British Journal of Urology , vol.74 , pp. 214-220
- Fox, S.B.¹ Persad, R.A.² Coleman, N.³ Day, C.A.⁴ Silcocks, P.B.⁵ Collins, C.C.⁶

7
- 0024416006
- Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function
- (1989) J Immun , vol.143 , pp. 1650-1655
- Guyre, P.M.¹ Graziano, R.F.² Vance, B.A.³ Morganelli, P.M.⁴ Fanger, M.W.⁵

8
- 0004605179
- Phase II trial of the bispecific antibody MDX-H210 (anti-HER2/neu x anti-CD64) combined with GM-CSF in patients with advanced prostate and renal cell carcinomas that express HER2/neu
- (1998) B J C , vol.78 , pp. 56
- James, N.¹ Atherton, P.² Koletsky, A.³ Tchekmedyian, N.⁴ Curnow, R.⁵

9
- 0003297513
- Phase II antibody trial of the bispecific antibody MDX-H210 (anti-HER2/neu x anti-CD64) combined with GM-CSF in patients with advanced prostate and renal cell carcinomas that express HER2/neu
- (1998) ProcASCO , vol.17
- James, N.¹ Atherton, P.² Koletsky, A.³ Tchekmedyian, N.⁴ Curnow, R.⁵

10
- 0031596534
- Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu in prostatic Adenocarcinomas
- (1998) J Clin Oncol , vol.16 , pp. 1302-1309
- Kallakury, B.V.S.¹ Sheehan, C.² Ambros, R.A.³ Fisher, H.A.⁴ Kaufman R.P., Jr.⁵ Muraca, P.J.⁶ Ross, J.S.⁷

11
- 33845382806
- Non-parametric estimation from incomplete observations
- Abstract
- (1958) J Amer Stat Assoc , vol.53 , pp. 457
- Kaplan, E.L.¹ Meier, P.²

12
- 0024358410
- GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against melanoma and neuroblastoma
- (1989) Blood , vol.73 , pp. 1936-1941
- Kushner, B.H.¹ Cheung, N.K.²

13
- 0030933521
- Tissue expression of Neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro
- (1997) Cancer J Scientific Amer , vol.3 , pp. 21-30
- Lyne, J.C.¹ Melhem, M.F.² Finley, M.D.G.G.³ Wen, D.⁴ Liu, Ph.D.N.⁵ Deng, B.S.D.H.⁶ Salup, R.⁷

14
- 0345337254
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
- (1998) J Clin Oncol , vol.16 , pp. 2825-2833
- McLaughlin, P.¹ Grillo-Lopez, A.J.² Link, B.K.³ Levy, R.⁴ Czuczman, M.S.⁵ Williams, M.E.⁶ Heyman, M.R.⁷ Bence-Bruckler, I.⁸ White, C.A.⁹ Cabanillas, F.¹⁰ Jain, V.¹¹ Ho, A.D.¹² Lister, J.¹³ Wey, K.¹⁴ Shen, D.¹⁵ Dallaire, B.K.¹⁶

15
- 0022633801
- The biology and function of the granulocyte macrophage colony stimulating factors
- (1986) Blood , vol.67 , pp. 257-267
- Metcalf, D.¹

16
- 0032794761
- Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer
- (1999) Inter J Cancer , vol.84 , pp. 421-425
- Morote, J.¹ De, T.I.² Caceres, C.³ Vallejo, C.⁴ Schwartz, S.J.⁵ Reventos, J.⁶

17
- 0017365573
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
- (1977) B J C , vol.35 , pp. 1-39
- Peto, R.¹ Pike, M.C.² Armitage, P.³ Breslow, N.E.⁴ Cox, D.R.⁵ Howard, S.V.⁶ Mantel, N.⁷ McPherson, K.⁸ Peto, J.⁹ Smith, P.G.¹⁰

18
- 0032995774
- A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies
- (1999) J Immuno , vol.22 , pp. 371-379
- Posey, J.A.¹ Raspet, R.² Verma, U.³ Deo, Y.M.⁴ Keller, T.⁵ Marshall, J.L.⁶ Hodgson, J.⁷ Mazumder, A.⁸ Hawkins, M.J.⁹

19
- 0027489913
- Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis
- (1993) Cancer , vol.72 , pp. 3020-3028
- Ross, J.S.¹ Nazeer, T.² Church, K.³ Amato, C.⁴ Figge, H.⁵ Rifkin, M.D.⁶ Fisher, H.A.G.⁷

20
- 0030978334
- Prognostic significance of HER-2/neu gene amplication status by fluorescence in situ hybridization of prostate carcinoma
- (1997) Ameri Cancer Soc , pp. 2162-2170
- Ross, J.S.¹ Sheehan, B.C.² Hayner-Buchan, M.A.M.³ Ambros, M.R.A.⁴ Kallakury, M.B.V.S.⁵ Kaufman, M.R.⁶ Fisher, M.H.A.G.⁷ Rifkin, M.M.D.⁸ Muraca, B.P.J.⁹

21
- 0030877481
- HER-2/neu gene application status in prostate cancer by fluorescence in situ hybridization
- (1997) Human Pathology , vol.28 , pp. 827-833
- Ross, J.S.¹ Sheehan, C.² Hayner-Buchan, A.M.³ Ambros, R.A.⁴ Kallakury, B.V.S.⁵ Kaufman, R.⁶ Fisher, H.A.G.⁷ Muraca, P.J.⁸

22
- 0027238684
- Overexpression of HER-2/neu may be an indicator of poor Prognosis in prostate cancer
- (1993) J Urol , vol.150 , pp. 126-131
- Sadasivan, R.¹ Morgan, R.² Jennings, S.³ Austenfeld, M.⁴ Van Veldhuizen, P.V.⁵ Stephens, R.⁶ Noble, M.⁷

23
- 33845720684
- Bioactivity of autologous irradiated prostate cancer vaccines generated by ex vivo gm-csf gene transfer
- Abstract 1205
- (1998) Proc ASCO , vol.17
- Simons, J.W.¹ Carducci, M.A.² Weber, C.E.³ De Marzo, A.⁴ Baccala, A.⁵ Cohen, L.⁶ Clift, S.M.⁷ Mikhak, B.⁸ Piantadosi, S.⁹ Partin, A.W.¹⁰ Carter, H.B.¹¹ Levitsky, H.I.¹²

24
- 0000405942
- Addition of HerceptinÖ (humanized anti-her2 antibody) to first line chemotherapy for her2 overexpressing metastatic breast cancer (her2+/mbc) markedly increases anticancer activity: A randomized, multinational controlled phase III trial
- (1998) Proc ASCO , vol.17
- Slamon, D.¹ Leyland-Jones, B.² Shak, S.³ Paton, V.⁴ Bajamonde, A.⁵ Fleming, T.⁶ Eiermann, W.⁷ Wolter, J.⁸ Baselga, J.⁹ Norton, L.¹⁰

25
- 14444269199
- Interferon-gamma and monoclonal antibody 1311-labeled CC49: Outcomes in patients with androgen-independent prostate cancer
- (1998) Clin Cancer Res , vol.4 , pp. 643-651
- Slovin, S.E.¹ Scher, H.I.² Divgi, C.R.³ Reuter, V.⁴ Sgouros, G.⁵ Moore, M.⁶ Weingard⁷ Pettengall, R.⁸ Imbriaco, M.⁹ El-Shirbiny, A.¹⁰ Finn, R.¹¹ Bronstein, J.¹² Brett Milenic, D.¹³ Dnistrian, A.¹⁴ Shapiro, L.¹⁵ Schlom, J.¹⁶ Larson, S.M.¹⁷

26
- 0032809320
- Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor
- (1999) Clin Cancer Res , vol.5 , pp. 1738-1744
- Small, E.J.¹ Reese, D.M.² Um, B.³ Whisenant, S.⁴ Dixon, S.C.⁵ Figg, W.D.⁶

27
- 0031832733
- Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
- (1998) J Clin Oncol , vol.16 , pp. 1835-1843
- Smith, D.C.¹ Dunn, R.L.² Strawderman, M.S.³ Pienta, K.J.⁴

28
- 0032211277
- The dynamics of prostate specific antigen in hormone refractory prostate carcinoma
- (1998) Cancer , vol.83 , pp. 1989-1994
- Vollmer, R.T.¹ Dawson, N.A.² Vogelzang, N.J.³

29
- 0033545848
- From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
- (1999) Proc Nat Acad Sci USA , vol.96 , pp. 5458-5463
- Yeh, S.¹ Lin, H.K.² Kang, H.Y.³ Thin, T.H.⁴ Lin, M.F.⁵ Chang, C.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.